Posts by Charles Corey Hardin, MD, PhD
-
COVID-19 ARDS Has Distinct Phenotypes Different from Those in "Classic" ARDS
Massachusetts General Hospital physicians have identified two phenotypes of acute respiratory distress syndrome (ARDS) associated with COVID-19 that are distinct in biochemical profiles and short-term mortality despite minimal differences in respiratory dynamics.
-
Editorial: Prone Positioning "Smooths the Edges" of Lung Protection During PEEP
Commenting on a recent pre-clinical study, C. Corey Hardin, MD, PhD, of the Division of Pulmonary and Critical Care Medicine, and a colleague explain why applying titrated positive end-expiratory pressure in the prone position helps protect the lungs of patients with acute respiratory distress syndrome.
-
Review: Evidence-Based Management of the Critically Ill Adult with COVID-19
Massachusetts General Hospital physicians have published guidance on treating critically ill adults with COVID-19 that synthesizes the pre-existing critical care literature with emerging data from observational reports and randomized controlled trials.
-
Commentary: Widely Reported Study of Therapeutic Anticoagulation for COVID-19 Has Serious Flaws
The report of an association between therapeutic anticoagulation and in-hospital survival among patients with COVID-19 has several serious limitations, including immortal time bias.
-
No Evidence to Support Novel Mechanism of Hypoxemia in COVID-19
According to Massachusetts General Hospital clinicians, observations of hypoxemia in COVID-19 are entirely consistent with known mechanisms and do not require the invocation of novel processes specific to SARS-CoV-2.
-
What Causes Hypoxemia in COVID-19? (Part II)
Many people are saying...hypoxemia in COVID-19 is something entirely new.
-
What Causes Hypoxemia in COVID-19? (Part I)
Many people are saying...hypoxemia in COVID-19 is something entirely new.
-
Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19 Is Typical of ARDS
Massachusetts General Hospital researchers find that patients with COVID-19 respiratory failure exhibited gas exchange, respiratory system mechanics and response to prone ventilation similar to that of prior large cohorts of patients with ARDS.
-
Surfactant Worth Studying as Treatment for COVID-19–Related ARDS
Massachusetts General Hospital researchers believe COVID-19 may represent an unexpected but worthwhile opportunity to revisit the therapeutic potential of administering exogenous surfactant to adults with acute respiratory distress syndrome.
-
Unconventional Ventilation Strategies Not Recommended for COVID-19–Related ARDS
Massachusetts General Hospital researchers explain that neither airway pressure release ventilation nor high-frequency oscillatory ventilation has been shown to improve mortality for patients with acute respiratory distress syndrome.
-
Surfactant and COVID-19
To date, trials of surfactant administration in adults have yet to bear fruit, but these negative results may well reflect technical or patient selection issues.
-
APRV and HFOV in COVID-19
Many people are saying...it's time to revive outdated modes of ventilation such as APRV and HFOV for COVID-19 associated ARDS.
-
COVID-19 Does Not Lead to "Atypical" ARDS
Arguments that COVID-19–associated respiratory failure is something other than acute respiratory distress syndrome (ARDS) are not supported by data or in-depth explanation.
-
Alveolar Recruitment in Patients with ARDS Related to COVID-19
In patients with acute respiratory distress syndrome related to COVID-19, care must be taken to choose the positive end-expiratory pressure that opens alveoli without over-distending the large amount of normal lung.
-
Didactic and Q&A: How to Care for Critically Ill Patients
The Department of Anesthesia, Critical Care and Pain Medicine at Massachusetts General Hospital held a virtual didactic and Q&A session on best practices for caring for critically-ill patients.
-
Inhaled Nitric Oxide Preferred to Epoprostenol in COVID-19 as Rescue Therapy
Despite frequent use in patients with acute respiratory distress syndrome, inhaled pulmonary vasodilators have never been shown to improve survival.
-
Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
In this Q&A, Lorenzo Berra, MD, and Charles Hardin, MD, PhD, of Massachusetts General Hospital explain the link between acute respiratory distress syndrome (ARDS) and share insight into upcoming research on antiviral treatment approaches.
Pulmonary and Critical Care Medicine
The Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital provides comprehensive care for the full range of respiratory conditions and diseases.Related Links
